Skip to main content
TipRanks
Go Ultimate75% OFF

Indoco Remedies Limited (INDOCO) Stock Price & Analysis

0 Followers

INDOCO Stock Chart & Stats

₹241.15₹16.55(7.37%)
At close: 3:30 PM GMT+5:30
₹225₹250₹275Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
INR 226.75 - INR 254.75
52-Week Range
INR 163.70 - INR 287.35
Previous Close
INR 224.60
Volume
80.97K
Average Volume (3M)
26.84K
Market Cap
INR 22.26B
Enterprise Value
INR 34.26B
Total Cash (Recent Filing)
INR 589.90M
Total Debt (Recent Filing)
INR 10.59B
Price to Earnings (P/E)
71.2
Beta
0.92
Next Earnings
Jan 26, 2027 (Est.)
Dividend Yield
0.08%

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Positive revenue growth indicates that the company continues to expand demand for its pharmaceutical products despite recent profitability pressure. Sustained top-line progress across domestic and international markets can support operating recovery if management converts sales growth into stronger margins.

Gross Margin

A gross margin of roughly 41% provides an important economic foundation for the business and shows that product-level economics remain reasonable. The improvement versus FY2024 creates potential for better earnings conversion if operating costs and other pressures are brought under control.

Business Model Breadth

Exposure to branded and generic formulations, APIs, contract manufacturing, and multiple therapeutic segments gives Indoco several routes to generate pharmaceutical revenue. Its domestic and international presence can broaden commercial reach and reduce reliance on a single product category.

Bears Say

Sustained Losses And Margin Compression

Two consecutive annual losses and an EBIT margin near 0.8% show that recent revenue growth is not translating into adequate operating profitability. Continued margin weakness could restrict reinvestment, weaken returns, and delay a durable recovery in shareholder earnings.

Higher Leverage

The sharp increase in debt relative to equity reduces financial flexibility while the company is reporting losses and negative returns. Higher leverage can increase the importance of earnings recovery, constrain capital allocation, and make the balance sheet more sensitive to prolonged operating weakness.

Negative Free Cash Flow

Deeply negative free cash flow indicates that operating cash generation has not covered investment and other cash requirements in the latest two years. This can limit internally funded growth, increase dependence on financing, and heighten execution risk if outflows remain elevated.

Indoco Remedies Limited News

INDOCO FAQ

What was Indoco Remedies Limited’s price range in the past 12 months?
Indoco Remedies Limited lowest stock price was ₹163.70 and its highest was ₹287.35 in the past 12 months.
What is Indoco Remedies Limited’s market cap?
Indoco Remedies Limited’s market cap is ₹22.26B.
When is Indoco Remedies Limited’s upcoming earnings report date?
Indoco Remedies Limited’s next earnings report is estimated for Jan 26, 2027 (not yet confirmed), which is in 67 days.
How were Indoco Remedies Limited’s earnings last quarter?
Indoco Remedies Limited released its earnings results on Oct 27, 2026. The company reported -₹2 earnings per share for the quarter, missing the consensus estimate of -₹0.25 by -₹1.75.
Is Indoco Remedies Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Indoco Remedies Limited pay dividends?
Indoco Remedies Limited pays an annual dividend of ₹0.2 which represents an annual dividend yield of 0.08%. See more information on Indoco Remedies Limited dividends here
What is Indoco Remedies Limited’s EPS estimate?
Indoco Remedies Limited’s EPS estimate is 2.60.
How many shares outstanding does Indoco Remedies Limited have?
Indoco Remedies Limited has 92,318,460 shares outstanding.
What happened to Indoco Remedies Limited’s price movement after its last earnings report?
Indoco Remedies Limited reported an EPS of -₹2 in its last earnings report, missing expectations of -₹0.25. Following the earnings report the stock price went up 0.387%.
Which hedge fund is a major shareholder of Indoco Remedies Limited?
Currently, no hedge funds are holding shares in IN:INDOCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology